Clinical trials: Crohn's
Colitis, Ulcerative, Crohn Disease
A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel Disease in Real Life Italian Setting
The purpose of this study is to characterize participants with Crohn's Disease (CD) and Ulcerative Colitis (UC) receiving guselkumab in a real-world setting, and to evaluate treatment persistence (continuation) and clinical…
- Conditions
- Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases
- Trial name
- GLAMOUR (NCT07851207)
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag Ltd.
Irritable Bowel Syndrome, Crohn Disease
Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis
The SIMBA Capsule is a small, single-use, ingestible capsule that allows for the non-invasive sampling of small bowel contents using purely mechanical means.
- Conditions
- Irritable Bowel Syndrome, Crohn Disease, Celiac Disease, Ulcerative Colitis
- Trial name
- NCT05633706
- Testing
- fluid biopsy capsule
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Crohn Disease
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
- Trial name
- NCT05906576
- Testing
- Infliximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Colitis, Ulcerative, Crohn Disease
A Real-World Study of Guselkumab Persistence and Effectiveness in Participants With Crohn's Disease or Ulcerative Colitis
The purpose of this study is to evaluate how long participants with moderate-to-severe Crohn's Disease (CD) and Ulcerative Colitis (UC) continue treatment with guselkumab in a real-world setting.
- Trial name
- GALILEO (NCT07848737)
- Volunteers
- 200 people
- Sponsor
- Janssen-Cilag, S.A.
Crohn's Disease
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.
- Trial name
- GALAXI (NCT03466411)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 579 sites in United States, Australia and 41 more
- Volunteers
- 1,409 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease, Colitis, Ulcerative
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
- Conditions
- Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
- Trial name
- UNITED (NCT05092269)
- Testing
- Ustekinumab
- Where
- 48 sites in United States, Argentina and 11 more
- Volunteers
- 159 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.
- Trial name
- DUET-CD (NCT05242471)
- Testing
- Guselkumab, Golimumab, JNJ-78934804
- Where
- 456 sites in United States, Australia and 34 more
- Volunteers
- 703 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease, Ulcerative Colitis
A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
The purpose of this study is to evaluate the long-term safety and clinical status of pediatric patients with Inflammatory Bowel Disease (IBD).
- Conditions
- Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
- Trial name
- DEVELOP (NCT00606346)
- Testing
- Anti TNF therapy including infliximab, No Biologics
- Where
- 62 sites in United States, Canada
- Volunteers
- 4,970 people
- Sponsor
- Janssen Biotech, Inc.
Crohn Disease
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
- Trial name
- GRAVITI (NCT05197049)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 345 sites in United States, Australia and 25 more
- Volunteers
- 350 people
- Sponsor
- Janssen Research & Development, LLC
Fistulizing Crohns Disease, Perianal Crohns Disease
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
- Trial name
- FUZION CD (NCT05347095)
- Testing
- Guselkumab
- Where
- 154 sites in United States, Australia and 21 more
- Volunteers
- 288 people
- Sponsor
- Janssen-Cilag Ltd.
Crohn's Disease
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical…
- Trial name
- MACARONI-23 (NCT05923073)
- Testing
- Guselkumab
- Where
- 85 sites in United States, Australia and 15 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately…
- Trial name
- NCT06233461
- Testing
- TAK-279
- Where
- 201 sites in United States, Australia and 23 more
- Volunteers
- 268 people
- Sponsor
- Takeda
Crohn's Disease
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan…
- Trial name
- REASON (NCT06408935)
- Testing
- Guselkumab
- Where
- 84 sites in United States, Australia and 12 more
- Volunteers
- 120 people
- Sponsor
- Janssen-Cilag Ltd.
Crohn's Disease
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels.
- Trial name
- Target CD (NCT06548542)
- Testing
- Risankizumab, Lutikizumab, Trosunilimab
- Where
- 255 sites in United States, Austria and 31 more
- Volunteers
- 590 people
- Sponsor
- AbbVie
Crohns Disease, Colitis, Ulcerative
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile…
- Conditions
- Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
- Trial name
- TRILOGY (NCT06663332)
- Testing
- Guselkumab
- Where
- 51 sites in United States, Argentina and 15 more
- Volunteers
- 196 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
The purpose of this study is to characterize participants with Crohn's Disease (CD) and Ulcerative Colitis (UC) treated with Guselkumab in a real-world setting, and to assess the clinical effectiveness (how well the treatment…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
- Trial name
- GORGEOUS (NCT07102368)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Janssen-Cilag G.m.b.H
Crohn Disease
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe…
- Trial name
- ICONIC-CD (NCT07196722)
- Testing
- Icotrokinra
- Where
- 372 sites in United States, Argentina and 26 more
- Volunteers
- 1,092 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Disease, Colitis, Ulcerative
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)
The purpose of this study is to evaluate the clinical effectiveness (how well the treatment works) of Guselkumab, by lines of treatment and subpopulations, and what are the outcomes of treatment (clinical outcomes) in adult…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
- Trial name
- GUSTO-UK (NCT07242248)
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- Janssen-Cilag Ltd.
Crohn Disease
A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)
The purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with…
- Trial name
- NCT07310095
- Testing
- Guselkumab (GUS)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Crohn Disease
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the…
- Trial name
- CHARGE (NCT07499232)
- Testing
- Guselkumab, Risankizumab
- Where
- 161 sites in United States, Austria and 15 more
- Volunteers
- 530 people
- Sponsor
- Janssen Research & Development, LLC